Literature DB >> 14734632

Neuroprotective effect of dextromethorphan in the MPTP Parkinson's disease model: role of NADPH oxidase.

Wei Zhang1, Tongguang Wang, Liya Qin, Hui-Ming Gao, Belinda Wilson, Syed F Ali, Wanqin Zhang, Jau-Shyong Hong, Bin Liu.   

Abstract

Parkinson's disease (PD) is a neurodegenerative movement disorder characterized by a progressive loss of dopaminergic neurons in the substantia nigra and depletion of the neurotransmitter dopamine in the striatum. Progress in the search for effective therapeutic strategies that can halt this degenerative process remains limited. Mechanistic studies using animal systems such as the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) rodent PD model have revealed the involvement of the brain's immune cells and free radical-generating processes. We recently reported that dextromethorphan (DM), a widely used anti-tussive agent, attenuated endotoxin-induced dopaminergic neurodegeneration in vitro. In the current study, we investigated the potential neuroprotective effect of DM and the underlying mechanism of action in the MPTP rodent PD model. Mice (C57BL/6J) that received daily MPTP injections (15 mg free base/kg body weight, s.c.) for 6 consecutive days exhibited significant degeneration of the nigrostriatal dopaminergic pathway. However, the MPTP-induced loss of nigral dopaminergic neurons was significantly attenuated in those mice receiving DM (10 mg/kg body weight, s.c.). In mesencephalic neuron-glia cultures, DM significantly reduced the MPTP-induced production of both extracellular superoxide free radicals and intracellular reactive oxygen species (ROS). Because NADPH oxidase is the primary source of extracellular superoxide and intracellular ROS, we investigated the involvement of NADPH oxidase in the neuroprotective effect of DM. Indeed, the neuroprotective effect of DM was only observed in the wild-type but not in the NADPH oxidase-deficient mice, indicating that NADPH oxidase is a critical mediator of the neuroprotective activity of DM. More importantly, due to its proven safety record of long-term clinical use in humans, DM may be a promising agent for the treatment of degenerative neurological disorders such as PD.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14734632     DOI: 10.1096/fj.03-0983fje

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  82 in total

Review 1.  NADPH oxidases: novel therapeutic targets for neurodegenerative diseases.

Authors:  Hui-Ming Gao; Hui Zhou; Jau-Shyong Hong
Journal:  Trends Pharmacol Sci       Date:  2012-04-11       Impact factor: 14.819

2.  Inflammation in patients with schizophrenia: the therapeutic benefits of risperidone plus add-on dextromethorphan.

Authors:  Shiou-Lan Chen; Sheng-Yu Lee; Yun-Hsuan Chang; Shih-Heng Chen; Chun-Hsieh Chu; Nian-Sheng Tzeng; I-Hui Lee; Po-See Chen; Tzung Lieh Yeh; San-Yuan Huang; Yen-Kuang Yang; Ru-Band Lu; Jau-Shyong Hong
Journal:  J Neuroimmune Pharmacol       Date:  2012-06-23       Impact factor: 4.147

Review 3.  Targeting NOX enzymes in the central nervous system: therapeutic opportunities.

Authors:  Silvia Sorce; Karl-Heinz Krause; Vincent Jaquet
Journal:  Cell Mol Life Sci       Date:  2012-05-30       Impact factor: 9.261

4.  PKU is a reversible neurodegenerative process within the nigrostriatum that begins as early as 4 weeks of age in Pah(enu2) mice.

Authors:  Jennifer E Embury; Catherine E Charron; Anatoly Martynyuk; Andreas G Zori; Bin Liu; Syed F Ali; Neil E Rowland; Philip J Laipis
Journal:  Brain Res       Date:  2006-11-15       Impact factor: 3.252

Review 5.  Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression.

Authors:  Hui-Ming Gao; Jau-Shyong Hong
Journal:  Trends Immunol       Date:  2008-07-01       Impact factor: 16.687

6.  Reactive microgliosis: extracellular micro-calpain and microglia-mediated dopaminergic neurotoxicity.

Authors:  Shannon Levesque; Belinda Wilson; Vincent Gregoria; Laura B Thorpe; Shannon Dallas; Vadim S Polikov; Jau-Shyong Hong; Michelle L Block
Journal:  Brain       Date:  2010-01-31       Impact factor: 13.501

7.  Saturation Binding of Nicotine to Synthetic Neuromelanin Demonstrated by Fluorescence Spectroscopy.

Authors:  Robert L Haining; Travis M Jones; Aubrey Hernandez
Journal:  Neurochem Res       Date:  2016-09-23       Impact factor: 3.996

8.  NADPH oxidase and aging drive microglial activation, oxidative stress, and dopaminergic neurodegeneration following systemic LPS administration.

Authors:  Liya Qin; Yuxin Liu; Jau-Shyong Hong; Fulton T Crews
Journal:  Glia       Date:  2013-03-28       Impact factor: 7.452

9.  Macrophage antigen complex-1 mediates reactive microgliosis and progressive dopaminergic neurodegeneration in the MPTP model of Parkinson's disease.

Authors:  Xiaoming Hu; Dan Zhang; Hao Pang; W Michael Caudle; Yachen Li; Huiming Gao; Yuxin Liu; Li Qian; Belinda Wilson; Donato A Di Monte; Syed F Ali; Jing Zhang; Michelle L Block; Jau-Shyong Hong
Journal:  J Immunol       Date:  2008-11-15       Impact factor: 5.422

10.  Hydrogen in drinking water reduces dopaminergic neuronal loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.

Authors:  Kyota Fujita; Toshihiro Seike; Noriko Yutsudo; Mizuki Ohno; Hidetaka Yamada; Hiroo Yamaguchi; Kunihiko Sakumi; Yukiko Yamakawa; Mizuho A Kido; Atsushi Takaki; Toshihiko Katafuchi; Yoshinori Tanaka; Yusaku Nakabeppu; Mami Noda
Journal:  PLoS One       Date:  2009-09-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.